pharmaphorum

AUGUST 5, 2022

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

Side effects 88

Side effects Marketing Pharma Medicine 88

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

NOVEMBER 6, 2022

The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement. It is the first approval for Beyfortus (nirsevimab) by any regulatory authority.

Marketing 64

Marketing Sales Manufacturing Pharma 64

pharmaphorum

JANUARY 18, 2023

German pharma group Bayer has made another play in the digital medical imaging category, buying Blackford Analysis and its artificial intelligence-based platform for radiological assessments. That pressure can lead to diagnostic errors, with a 2018 study suggesting that there are 40 million errors involving imaging worldwide every year.

Medical 59

Medical Pharma Media Sales 59

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP? So why will obicetrapib avoid the pitfalls of its predecessors?

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. Secondly, pressure on healthcare spending is leading to greater consolidation. Overall, the industry is steadily becoming more consolidated and is likely to continue to do so.

Healthcare 91

Healthcare Healthcare Manufacturing Marketing 91

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

European Pharmaceutical Review

AUGUST 22, 2024

billion” last year, two key players in the market, namely Novo Nordisk and Eli Lilly and Company, are set to lead the market, the analytics company forecasts: “collectively capturing 94 percent of the total 2030 GLP-1R sales”. Eli Lilly shared that production of the medicines will commence at the Lebanon site towards the end of 2026.

Medicine 59

Medicine Marketing Manufacturing Sales 59

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. The buyout – for $12.50 Lilly said there’s no guarantee the CVRs will be paid, and that the payments will shrink by $0.42

Medicine 52

Medicine FDA Patients Pharma 52

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. This article was written by Clarivate Lead Healthcare Research and Data Analysts Renée Burnham, Michelle La Vone and Paula Wade. Key acquisitions by U.S. healthcare organizations Company Founded Type No. The post U.S.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Pharma simply has less interactive time with doctors. Launch opportunity is reduced. That impacts launches most.

Doctors 59

Doctors Medicine Marketing Sales 59

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. percent between 2021 and 2026 (the forecast period). Billion by 2026, achieving a 5.6 Meanwhile, the presence of a significant number of pharmaceutical and biopharmaceutical companies, and several of the leading firms worldwide puts the US and Europe ahead in the global market. billion by the year 2026.

Manufacturing 98

Manufacturing Marketing Pharma Healthcare 98

pharmaphorum

DECEMBER 14, 2022

“We are proud to contribute to the Italian and broader global ecosystem supporting the creation and growth of start-ups solving unmet medical needs,” says Filippo Piazza, associate at Angelini Ventures who is leading this strategic partnership. By 2026, Argobio Studio SAS will create and launch five or more biotech companies.

Healthcare 105

Healthcare Healthcare Patients Management 105

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52

World of DTC Marketing

JULY 28, 2022

Still, the pharma industry is fighting hard to keep it off the table. Yet, high drug prices lead to soaring out-of-pocket costs , dangerous drug rationing , and a depletion of limited financial resources —especially for those with fixed incomes. Pharma is a very profitable industry. The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

There are two ways telehealth waivers can be extended through 2025 – via The Centers for Medicare & Medicaid Rule and legislatively through 2026 via H.R. This post was written by Bill Melville, Lead Healthcare Research and Data Analyst; Roy Moore, Senior Healthcare Research and Data Analyst; Valerie E.

Healthcare 52

Healthcare Healthcare Government Insurance 52